CD28 and cancer: Several studies have documented that soluble immune checkpoints and natural killer markers including PD-L1, PD-1, CTLA-4, TIM-3, IDO, NKG2DL, CD27, CD28 etc. can serve as effective biomarkers for monitoring and predicting the treatment response in different cancers as reviewed by Raza et al.